Developing a radiosensitivity gene signature for Caucasian patients with breast cancer

Ji, Yiqin; Jiang, Qinghua; Jian, Guohao; Sun, Haitong; Wang, Yamin; Qin, Hualong; Zhang, Shuyu; Cao, Jianping; Tang, Zaixiang

doi:10.3892/or.2018.6567

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, radiosensitive patients were defined as a group of patients who had better overall survival after receiving radiotherapy compared with nonradiotherapy. Radiosensitive gene was defined as the genes which are associated and could be used to identify the radiosensitive patients [ 17 ]. The genes involved in the PD-L1 pathway in cancer were found in the Kyoto Encyclopedia of Genes and Genomes (KEGG).…”

Section: Methodsmentioning

confidence: 99%

Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer

Yan

et al. 2020

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

The PD-1/PD-L1 pathway plays an important role in the treatment of cancers as immune checkpoint. However, the association of genes involved in the PD-L1 pathway and radiosensitivity of gastric cancer has not been fully characterized. This study aims to explore the relationship between the expression levels of genes involved in the PD-L1 pathway and radiosensitivity for gastric cancer patients. A total of 367 patients with clinical survival information and radiotherapy information were obtained in The Cancer Genome Atlas (TCGA). Genes involved in the PD-L1 pathway were categorized into high and low expression level groups according to the median value. The Cox proportional hazards model was used to find the association between gene expression level and radiosensitivity. The results show that high expression levels of CD274, EGFR, RAF1, RPS6KB1, PIK3CA, MTOR, CHUK, NFKB1, TRAF6, FOS, NFATC1, and HIF1A were associated with radiosensitivity of gastric cancer. While low expression level of HRAS was also associated with radiosensitivity in gastric cancer. The rates of a new tumor event and disease progression were lower for radiosensitivity patients than other patients. The relationship between the expression level of CD274 and other genes involved in the PD-L1 pathway is significant. GO (Gene Ontology) analysis shows that the biological process of 13 genes was mainly related to innate immune response activating the cell surface receptor signaling pathway. KEGG analysis demonstrated that 13 genes in gastric cancer are mainly related to the PD-L1 expression and PD-1 checkpoint pathway in cancer. The correlation between the expression level of CD274 and other genes involved in the PD-L1 pathway is significant. The present study offered more evidence for using PD-L1 and genes involved in the PD-L1 pathway as potential biomarkers to predict radiosensitive patients with gastric cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer

Yan

et al. 2020

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the present study, radiotherapy sensitivity was defined as the improved survival benefits of the patients receiving radiotherapy, compared with the patients who did not receive radiotherapy [22, 23]. The gene that can predict individual radiosensitivity could be a potential biomarker for radiosensitivity prediction.…”

Section: Data Sources and Methodsmentioning

confidence: 99%

Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer

Sun

et al. 2019

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Human gene GLIS family zinc finger 2 (GLIS2) is a member of GLI-similar zinc finger protein family. Previous studies indicated GLIS2 gene involved in tumorigenesis mechanisms. However, the association between GLIS2 expression and radiosensitivity of gastric cancer has not been well understood. In this study, we used the gastric cancer database in TCGA, and significant association was observed between the low expression of GLIS2 and radiosensitivity of patients with gastric cancer. The adjusted HR values for radiotherapy were 0.162(0.035-0.756) and 0.089(0.014-0.564), with p values 0.021 and 0.010, respectively, in training and testing data, for these patients with low expression of GLIS2, while for patients with high expression of GLIS2, there was no significant survival difference between radiotherapy and nonradiotherapy groups. The adjusted HR were 0.676(0.288-1.586) and 0.508(0.178-1.450), with p values 0.368 and 0.206 in training and testing data, respectively. Further study showed that, for low expression patients, radiotherapy did not significantly increase new tumor event rate and disease progression rate, which partially supported our assumption. These results suggested that low expression of GLIS2 might significantly associate with the radiosensitivity of patients with gastric cancer. The GLIS2 gene might be a potential effective molecular marker of gastric cancer for precise radiotherapy.

show abstract

“…Seven studies used TCGA data only to generate signatures for soft tissue sarcoma (STS) (n = 2) [17,18], gastric cancer (n = 1) [19], HNSCC (n = 2) [20,33], breast cancer (n = 1) [24] and cervix cancer (n = 1) [35]; four of these used a cross-validated adaptive signature design (CVASD) approach to derive and validate the signature within the same dataset, two split the TCGA cohort into training and validation and one used the TCGA to validate a signature derived in a very small independent cohort. The remaining five studies used multiple publicly available microarray/RNA-Seq cohorts to derive signatures for breast cancer (n = 4) [14,25,32,36] and glioma/glioblastoma (n = 1) [39].…”

Section: Other In Vivo Derived Radiosensitivity Signaturesmentioning

confidence: 99%

Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review

Bleaney,

Abdelaal,

Reardon

et al. 2024

Cancers

View full text Add to dashboard Cite

Modern advanced radiotherapy techniques have improved the precision and accuracy of radiotherapy delivery, with resulting plans being highly personalised based on individual anatomy. Adaptation for individual tumour biology remains elusive. There is an unmet need for biomarkers of intrinsic radiosensitivity that can predict tumour response to radiation to facilitate individualised decision-making, dosing and treatment planning. Over the last few decades, the use of high throughput molecular biology technologies has led to an explosion of newly discovered cancer biomarkers. Gene expression signatures are now used routinely in clinic to aid decision-making regarding adjuvant systemic therapy. They have great potential as radiotherapy biomarkers. A previous systematic review published in 2015 reported only five studies of signatures evaluated for their ability to predict radiotherapy benefits in clinical cohorts. This updated systematic review encompasses the expanded number of studies reported in the last decade. An additional 27 studies were identified. In total, 22 distinct signatures were recognised (5 pre-2015, 17 post-2015). Seventeen signatures were ‘radiosensitivity’ signatures and five were breast cancer prognostic signatures aiming to identify patients at an increased risk of local recurrence and therefore were more likely to benefit from adjuvant radiation. Most signatures (15/22) had not progressed beyond the discovery phase of development, with no suitable validated clinical-grade assay for application. Very few signatures (4/17 ‘radiosensitivity’ signatures) had undergone any laboratory-based biological validation of their ability to predict tumour radiosensitivity. No signatures have been assessed prospectively in a phase III biomarker-led trial to date and none are recommended for routine use in clinical guidelines. A phase III prospective evaluation is ongoing for two breast cancer prognostic signatures. The most promising radiosensitivity signature remains the radiosensitivity index (RSI), which is used to calculate a genomic adjusted radiation dose (GARD). There is an ongoing phase II prospective biomarker-led study of RSI/GARD in triple negative breast cancer. The results of these trials are eagerly anticipated over the coming years. Future work in this area should focus on (1) robust biological validation; (2) building biobanks alongside large radiotherapy randomised controlled trials with dose variance (to demonstrate an interaction between radiosensitivity signature and dose); (3) a validation of clinical-grade cost-effective assays that are deliverable within current healthcare infrastructure; and (4) an integration with biomarkers of other determinants of radiation response.

show abstract

Developing a radiosensitivity gene signature for Caucasian patients with breast cancer

Cited by 5 publications

References 32 publications

Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer

Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer

Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer

Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review

Contact Info

Product

Resources

About